[Cavitating pneumonia in a patient infected with human immunodeficiency virus].
Delgado
M
M
Servicio de Endocrinología, Hospital La Paz, Universidad Autónoma, Madrid.
Sancho
T
T
Andreu
M
M
Ortega
N
N
García
J
J
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology*; D000151:Acinetobacter Infections / Q000188:drug therapy / Q000209:etiology*; D000193:Actinomycetales Infections / Q000188:drug therapy / Q000209:etiology*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D006556:Heroin Dependence / Q000150:complications; D006801:Humans; D015378:Imipenem / Q000627:therapeutic use; D016867:Immunocompromised Host; D008297:Male; D009296:Nasal Cavity / Q000382:microbiology; D018410:Pneumonia, Bacterial / Q000188:drug therapy / Q000209:etiology* / Q000382:microbiology; D016929:Rhodococcus equi / Q000302:isolation & purification*; D017828:Rifabutin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000209:etiology*; D015819:Substance Abuse, Intravenous / Q000150:complications; D014640:Vancomycin / Q000627:therapeutic use
D019380:Anti-HIV Agents; D017828:Rifabutin; D014640:Vancomycin; D015378:Imipenem; D017291:Clarithromycin